サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1298097

CAR-T細胞療法市場、シェア、規模、動向、産業分析レポート、標的抗原別（CD19/CD22、BCMA、その他）、適応症別、地域別、セグメント予測、2023年～2032年

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
CAR-T細胞療法市場、シェア、規模、動向、産業分析レポート、標的抗原別（CD19/CD22、BCMA、その他）、適応症別、地域別、セグメント予測、2023年～2032年
出版日: 2023年05月23日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のCAR-T細胞療法市場規模は2032年までに1,186億8,068万米ドルに達する見込みです。同レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

CAR-T細胞療法市場は、がんと闘うために免疫系を利用することから大きな成長を遂げています。この画期的なアプローチでは、白血球の一種である患者自身のT細胞を改変し、その表面にキメラ抗原受容体（CAR）を発現させる。このCARによって、T細胞はがん細胞内の特定の抗原を認識し、標的とすることができるようになり、がん細胞の破壊につながります。CAR-T療法は、特定の血液悪性腫瘍の治療において有望な結果を示しており、他のタイプのがんにおいてもその可能性が検討されています。

CAR-T治療では、患者の血液からT細胞を取り出し、研究室で遺伝子組み換えを行い、がん細胞に多く含まれるタンパク質に結合する受容体を産生させる。その後、これらの改変されたCAR-T細胞が大量に生産され、患者に投与されます。がん細胞を見つけて攻撃するT細胞の能力を高めることで、CAR-T療法はがん治療に革命を起こす可能性を秘めています。

しかし、COVID-19パンデミックはCAR-T細胞療法市場に影響を与えています。サプライチェーンの閉鎖や混乱により、CAR-T細胞製造に必要な原材料の生産や入手に遅延や中断が生じています。このため、ライフサイエンス企業やバイオファーマ企業は、CAR-T細胞製造のための新たな原材料を待たなければならないという課題を抱えています。このようなサプライチェーンの問題に対処し、この困難な時期にCAR-T細胞の製造をサポートするための原材料の安定供給を確保するための取り組みが進行中です。

CAR-T細胞療法市場レポートハイライト

CD19/CD22は最大の市場シェアを持つCAR-T細胞療法です。白血病やリンパ腫の治療で顕著な臨床結果を示し、規制当局の承認を得て、患者の寛解達成に有効であることが証明されています。

DLBCL（びまん性大細胞型B細胞リンパ腫）は、CAR-T細胞療法市場で顕著な適応症であり、大きな市場シェアを占めています。この急成長中のB細胞由来のがんは、リンパ系に影響を及ぼす非ホジキンリンパ腫の一種です。

北米は、がん罹患率の上昇とバイオテクノロジー産業の成長に牽引され、同市場をリードするとみられます。それに伴い、同地域のがん治療に対する需要も増加しています。

世界の主要市場企業は以下の通り：Amgen（米国）、Bellicum Pharmaceuticals（米国）、Bluebird Bio（米国）、Caribou Biosciences（米国）、Celgene、Cellectis、Celyad、Gilead Sciences、Intellia Therapeutics、Johnson &Johnson、Merck KGaA、Nanjing Legend Biotechnology、Noile-Immune Biotech、Novartis International AG、Pfizer Inc.、Sangamo Therapeutics、Servier Laboratories などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のCAR-T細胞療法市場の洞察

  • CAR-T細胞療法市場- 業界スナップショット
  • CAR-T細胞療法市場力学
    • 促進要因と機会
      • CAR-T細胞療法に関する意識の高まり
      • がん治療における理想的な治療法の需要の増加
    • 抑制要因と課題
      • CAR-T細胞療法の高額な費用
  • PESTLE分析
  • CAR-T細胞療法業界の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のCAR-T細胞療法市場、標的抗原別

  • 主な調査結果
  • イントロダクション
  • CD19/CD22
  • BCMA（B細胞成熟抗原）
  • その他（MUC16、L1CAM、ROR1、EGFRvIII、PSCA、NKR-2、IL13Ra2、LewisY）

第6章 世界のCAR-T細胞療法市場、適応症別

  • 主な調査結果
  • イントロダクション
  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • 乳腺症
  • 骨髄線維症
  • MLL
  • 胸腺がん
  • 膠芽腫
  • AML
  • その他

第7章 世界のCAR-T細胞療法市場、地域別

  • 主な調査結果
  • イントロダクション
    • CAR-T細胞療法市場評価、地域、2019-2032年
  • CAR-T細胞療法市場-北米
    • 北米：CAR-T細胞療法市場、適応症別、2019～2032年
    • 北米：CAR-T細胞療法市場、標的抗原別、2019～2032年
    • CAR-T細胞療法市場-米国
    • CAR-T細胞療法市場- カナダ
  • CAR-T細胞療法市場- 欧州
    • 欧州：CAR-T細胞療法市場、適応症別、2019～2032年
    • 欧州：CAR-T細胞療法市場、標的抗原別、2019～2032年
    • CAR-T細胞療法市場- 英国
    • CAR-T細胞療法市場- フランス
    • CAR-T細胞療法市場- ドイツ
    • CAR-T細胞療法市場- イタリア
    • CAR-T細胞療法市場- スペイン
    • CAR-T細胞療法市場- オランダ
    • CAR-T細胞療法市場- ロシア
  • CAR-T細胞療法市場- アジア太平洋
    • アジア太平洋地域：CAR-T細胞療法市場、適応症別、2019～2032年
    • アジア太平洋地域：CAR-T細胞療法市場、標的抗原別、2019～2032年
    • CAR-T細胞療法市場- 中国
    • CAR-T細胞療法市場- インド
    • CAR-T細胞療法市場- マレーシア
    • CAR-T細胞療法市場- 日本
    • CAR-T細胞療法市場- インドネシア
    • CAR-T細胞療法市場- 韓国
  • CAR-T細胞療法市場-中東およびアフリカ
    • 中東およびアフリカ：CAR-T細胞療法市場、適応症別、2019～2032年
    • 中東およびアフリカ：CAR-T細胞療法市場、標的抗原別、2019～2032年
    • CAR-T細胞療法市場- サウジアラビア
    • CAR-T細胞療法市場- アラブ首長国連邦
    • CAR-T細胞療法市場- イスラエル
    • CAR-T細胞療法市場- 南アフリカ
  • CAR-T細胞療法市場-ラテンアメリカ
    • ラテンアメリカ：CAR-T細胞療法市場、適応症別、2019-2032年
    • ラテンアメリカ：CAR-T細胞療法市場、標的抗原別、2019～2032年
    • CAR-T細胞療法市場- メキシコ
    • CAR-T細胞療法市場- ブラジル
    • CAR-T細胞療法市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡張
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Amgen Inc.（US）
  • Bellicum Pharmaceuticals, Inc
  • Bellicum Pharmaceuticals, Inc.（US）
  • Bluebird Bio（US）
  • Caribou Biosciences, Inc.（US）
  • Cellectis
  • Celyad
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Merck KGaA
  • Nanjing Legend Biotechnology Co., Ltd
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc
  • Sangamo Therapeutics, Inc
  • Servier Laboratories
図表

List of Tables

  • Table 1 Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 2 Global CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 3 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 5 North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 6 U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 7 U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 8 Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 9 Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 10 Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 11 Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 12 UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 13 UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 14 France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 15 France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 16 Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 17 Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 18 Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 19 Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 20 Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 21 Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 22 Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 23 Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 24 Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 25 Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 28 China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 29 China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 30 India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 31 India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 32 Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 33 Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 34 Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 35 Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 36 Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 37 Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 38 South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 39 South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 44 UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 45 UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 46 Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 47 Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 48 South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 49 South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 50 Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 51 Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 52 Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 53 Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 54 Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 55 Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 56 Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 57 Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global CAR-T Cell Therapy Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Indication
  • Figure 7 Global CAR-T Cell Therapy Market, by Indication, 2022 & 2032 (USD Million)
  • Figure 8 Market by Target Antigen
  • Figure 9 Global CAR-T Cell Therapy Market, by Target Antigen, 2022 & 2032 (USD Million)
  • Figure 10 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - CAR-T Cell Therapy Market
目次
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 118,680.68 million by 2032, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The CAR-T cell therapy market is experiencing significant growth as it utilizes the immune system to combat cancer. This groundbreaking approach involves modifying a patient's own T cells, a type of white blood cell, to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T cells to recognize and target specific antigens in cancer cells, leading to their destruction. CAR-T therapy has shown promising results in treating specific blood malignancies and is being explored for its potential in other types of cancer.

In CAR-T treatment, T cells from the patient's blood are taken out and genetically modified in a lab to produce receptors that bind to proteins prevalent in cancer cells. Large quantities of these modified CAR-T cells are then produced and administered to the patient. By enhancing the T cells' ability to locate and attack cancer cells, CAR-T therapy has the potential to revolutionize cancer treatment.

However, the COVID-19 pandemic has impacted the CAR-T cell therapy market. Lockdowns and disruptions in the supply chain have resulted in delays and interruptions in the production and availability of raw materials needed for CAR-T cell manufacturing. This has created challenges for life science and biopharma companies, causing them to wait for new raw materials for CAR-T cell production. Efforts are underway to address these supply chain issues and ensure a steady supply of materials to support the manufacturing of CAR-T cells during these challenging times.

CAR-T Cell Therapy Market Report Highlights

CD19/CD22 is the CAR-T cell therapy with the largest market share. It has shown remarkable clinical results in leukemia and lymphoma treatment, gaining regulatory approval and proving effective in achieving patient remission.

DLBCL (Diffuse Large B-cell Lymphoma) is a prominent indication in the CAR-T cell therapy market, holding a significant market share. This fast-growing cancer of B-cell origin is a prevalent form of non-Hodgkin lymphoma affecting the lymphatic system.

North America is set to lead the market, driven by rising cancer incidence and the growing biotechnology industry. The region's demand for cancer treatments is increasing accordingly.

The global key market players include: Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:

CAR-T Cell Therapy, Target Antigen Outlook (Revenue - USD Million, 2019 - 2032)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue - USD Million, 2019 - 2032)

  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL
  • Thymic Cancer
  • Glioblastoma
  • AML
  • Others

CAR-T Cell Therapy, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Austria
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global CAR-T Cell Therapy Market Insights

  • 4.1. CAR-T Cell Therapy Market - Industry Snapshot
  • 4.2. CAR-T Cell Therapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in awareness regarding CAR T-cell therapy
      • 4.2.1.2. Increase in demand of ideal therapeutics for treatment of cancer
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of CAR T-cell therapies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. CAR-T Cell Therapy Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global CAR-T Cell Therapy Market, by Target Antigen

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2019-2032 (USD Million)
  • 5.3. CD19/CD22
    • 5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2019-2032 (USD Million)
  • 5.4. BCMA (B-Cell Maturation Antigen)
    • 5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2019-2032 (USD Million)
  • 5.5. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
    • 5.5.1. Global CAR-T Cell Therapy Market, by Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY), by Region, 2019-2032 (USD Million)

6. Global CAR-T Cell Therapy Market, by Indication

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • 6.3. DLBCL
    • 6.3.1. Global CAR-T Cell Therapy Market, by DLBCL, by Region, 2019-2032 (USD Million)
  • 6.4. ALL
    • 6.4.1. Global CAR-T Cell Therapy Market, by ALL, by Region, 2019-2032 (USD Million)
  • 6.5. CLL
    • 6.5.1. Global CAR-T Cell Therapy Market, by CLL, by Region, 2019-2032 (USD Million)
  • 6.6. MM
    • 6.6.1. Global CAR-T Cell Therapy Market, by MM, by Region, 2019-2032 (USD Million)
  • 6.7. FL
    • 6.7.1. Global CAR-T Cell Therapy Market, by FL, by Region, 2019-2032 (USD Million)
  • 6.8. Mastozytosis
    • 6.8.1. Global CAR-T Cell Therapy Market, by Mastozytosis, by Region, 2019-2032 (USD Million)
  • 6.9. Myeloid Fibrosis
    • 6.9.1. Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, by Region, 2019-2032 (USD Million)
  • 6.10. MLL
    • 6.10.1. Global CAR-T Cell Therapy Market, by MLL, by Region, 2019-2032 (USD Million)
  • 6.11. Thymic Cancer
    • 6.11.1. Global CAR-T Cell Therapy Market, by Thymic Cancer, by Region, 2019-2032 (USD Million)
  • 6.12. Glioblastoma
    • 6.12.1. Global CAR-T Cell Therapy Market, by Glioblastoma, by Region, 2019-2032 (USD Million)
  • 6.13. AML
    • 6.13.1. Global CAR-T Cell Therapy Market, by AML, by Region, 2019-2032 (USD Million)
  • 6.14. Others
    • 6.14.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2019-2032 (USD Million)

7. Global CAR-T Cell Therapy Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. CAR-T Cell Therapy Market - North America
    • 7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.3. CAR-T Cell Therapy Market - U.S.
      • 7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.4. CAR-T Cell Therapy Market - Canada
      • 7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.4. CAR-T Cell Therapy Market - Europe
    • 7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.3. CAR-T Cell Therapy Market - UK
      • 7.4.3.1. UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.3.2. UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.4. CAR-T Cell Therapy Market - France
      • 7.4.4.1. France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.4.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.5. CAR-T Cell Therapy Market - Germany
      • 7.4.5.1. Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.6. CAR-T Cell Therapy Market - Italy
      • 7.4.6.1. Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.7. CAR-T Cell Therapy Market - Spain
      • 7.4.7.1. Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.8. CAR-T Cell Therapy Market - Netherlands
      • 7.4.8.1. Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.9. CAR-T Cell Therapy Market - Russia
      • 7.4.9.1. Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.5. CAR-T Cell Therapy Market - Asia Pacific
    • 7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.3. CAR-T Cell Therapy Market - China
      • 7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.4. CAR-T Cell Therapy Market - India
      • 7.5.4.1. India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.4.2. India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.5. CAR-T Cell Therapy Market - Malaysia
      • 7.5.5.1. Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.6. CAR-T Cell Therapy Market - Japan
      • 7.5.6.1. Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.7. CAR-T Cell Therapy Market - Indonesia
      • 7.5.7.1. Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.8. CAR-T Cell Therapy Market - South Korea
      • 7.5.8.1. South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.6. CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.3. CAR-T Cell Therapy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.4. CAR-T Cell Therapy Market - UAE
      • 7.6.4.1. UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.5. CAR-T Cell Therapy Market - Israel
      • 7.6.5.1. Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.6. CAR-T Cell Therapy Market - South Africa
      • 7.6.6.1. South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.7. CAR-T Cell Therapy Market - Latin America
    • 7.7.1. Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.7.2. Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.3. CAR-T Cell Therapy Market - Mexico
      • 7.7.3.1. Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.4. CAR-T Cell Therapy Market - Brazil
      • 7.7.4.1. Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.5. CAR-T Cell Therapy Market - Argentina
      • 7.7.5.1. Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Amgen Inc. (US)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bellicum Pharmaceuticals, Inc
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bellicum Pharmaceuticals, Inc. (US)
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bluebird Bio (US)
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Caribou Biosciences, Inc. (US)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Cellectis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Celyad
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Gilead Sciences, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Intellia Therapeutics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Johnson & Johnson
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Merck KGaA
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Nanjing Legend Biotechnology Co., Ltd
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Noile-Immune Biotech
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Novartis International AG
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Pfizer Inc
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Sangamo Therapeutics, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Servier Laboratories
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development